Orders +4%, sales -9%, adj. EBITA -22% vs. our estimates EBITA miss driven by 3 high-volume delivery...
Redeye comments on BrightBid’s Q1 report, with numbers aligning with the preliminary figures.
Redeye comments on the announcement of SEK13.6m loan, a directed issue of warrants and a SEK10.
Redeye provides an in-depth take on AroCell’s Q1 report.
Suominen's Q1 was fairly in line with Vara Research consensus, while the company also announced a la...
Redeye strengthens its positive view of Avensia following a strong Q1 report, showing high growth an...
Preliminary Q1 figures: sales -17% y-o-y, -13% vs. ABGSCe Weak market and client phase-outs, but sur...
Surprisingly high costs, but solid top-line and customer intake We cut '25e EBITA by 7%, but raise '...
Cost reduction initiatives in DE and NL short-term Focus on margin improvement journey and selective...
Problemen i Storbritannien och uppskalningen av organisationen tynger resultaten tillfälligt, men an...
We hosted the new CEO Magnus Lönn this morning Strategy to replicate the Nordic & Baltics success to...
Redeye comments on Avensia’s Q1 report, beating our expectations significantly on both sales and EBI...
Enersense won a contract with Fingrid to build the 400/110 kV transformer substation and related pow...
Inledningen av 2025 var i linje med våra förväntningar.
Redeye is positive to GomSpace’s trading update published this morning, which included solid growth ...
Sales trough reached, return to EBIT growth in Q3e '25e-'27e EBIT down 29-13% on FX and system sales...
Suominen Q1 comparable EBITDA of EUR 4.1m came fairly in line with Vara Research consensus expectati...
Redeye provides an initial comment on the Q1 2025 report from Cheffelo, which was in line with annou...
Redeye returns with an update following AlzeCure's Q1 2025 earnings release, which aligned with our ...
Investors House reported Q1 revenues of EUR 2.7m, 4% below our estimate.
